Where I see patients (1)
My reviews
Selected research
-
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
Leukemia & lymphoma
-
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.
Journal for immunotherapy of cancer
-
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target.
Nature cancer
Clinical trials
Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis ...
The proportion of responder (complete response (CR) or partial response (PR)) or non-responder at the end of induction using a physician developed response criteria will be reported. Those with non-malignant HLH (nmHLH) will be as...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 353-2421
4.9